Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986012 plus carboplatin, etoposide, and nivolumab for first-line extensive-stage small cell lung cancer
jRCT2051210111Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2022
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of Atigotatug in small cell lung cancer (SCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 3 more. Started Jan 2022; status: completed.
02
Drugs
Atigotatug
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2051210111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210111.